vs
Midland States Bancorp, Inc.（MSBI）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是Midland States Bancorp, Inc.的1.6倍（$127.1M vs $79.5M），过去两年再鼎医药的营收复合增速更高（20.8% vs -6.4%）
雷德尼爾銀行公司是總部位於西雅圖的雷德尼爾國家銀行的母公司，該銀行是華盛頓州的本土銀行，在全州設有多家網點。其發展歷史可追溯至1889年理查德·霍利約克創辦的通商國家銀行，1974年正式更名為雷德尼爾國家銀行，此後陸續收購機構，將業務拓展至阿拉斯加與俄勒岡地區。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
MSBI vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.6倍
$79.5M
两年增速更快
ZLAB
近两年复合增速
-6.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $79.5M | $127.1M |
| 净利润 | $18.5M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | — | -54.6% |
| 净利率 | 23.2% | — |
| 营收同比 | — | 17.1% |
| 净利润同比 | 739.3% | — |
| 每股收益（稀释后） | $0.74 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MSBIZLAB
| Q1 26 | $79.5M | — | ||
| Q4 25 | $85.6M | $127.1M | ||
| Q3 25 | $81.1M | $115.4M | ||
| Q2 25 | $82.2M | $109.1M | ||
| Q1 25 | $76.1M | $105.7M | ||
| Q4 24 | $93.9M | $108.5M | ||
| Q3 24 | $92.7M | $101.8M | ||
| Q2 24 | $90.9M | $100.1M |
净利润MSBIZLAB
| Q1 26 | $18.5M | — | ||
| Q4 25 | $-2.9M | — | ||
| Q3 25 | $7.6M | $-36.0M | ||
| Q2 25 | $12.0M | $-40.7M | ||
| Q1 25 | $-141.0M | $-48.4M | ||
| Q4 24 | $-30.8M | — | ||
| Q3 24 | $20.4M | $-41.7M | ||
| Q2 24 | $25.7M | $-80.3M |
毛利率MSBIZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% |
营业利润率MSBIZLAB
| Q1 26 | — | — | ||
| Q4 25 | -5.5% | -54.6% | ||
| Q3 25 | 13.9% | -42.3% | ||
| Q2 25 | 18.1% | -50.3% | ||
| Q1 25 | -181.2% | -53.3% | ||
| Q4 24 | -66.5% | -62.6% | ||
| Q3 24 | 26.9% | -66.6% | ||
| Q2 24 | 35.0% | -76.0% |
净利率MSBIZLAB
| Q1 26 | 23.2% | — | ||
| Q4 25 | -4.9% | — | ||
| Q3 25 | 9.3% | -31.2% | ||
| Q2 25 | 14.6% | -37.3% | ||
| Q1 25 | -185.4% | -45.8% | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | 22.1% | -40.9% | ||
| Q2 24 | 28.3% | -80.2% |
每股收益（稀释后）MSBIZLAB
| Q1 26 | $0.74 | — | ||
| Q4 25 | $-0.22 | $-0.05 | ||
| Q3 25 | $0.24 | $-0.03 | ||
| Q2 25 | $0.44 | $-0.04 | ||
| Q1 25 | $-6.58 | $-0.04 | ||
| Q4 24 | $-1.49 | $-0.09 | ||
| Q3 24 | $0.83 | $-0.04 | ||
| Q2 24 | $1.06 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $89.4M | $689.6M |
| 总债务越低越好 | $33.2M | — |
| 股东权益账面价值 | $569.5M | $715.5M |
| 总资产 | $6.5B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.06× | — |
8季度趋势，按日历期对齐
现金及短期投资MSBIZLAB
| Q1 26 | $89.4M | — | ||
| Q4 25 | $127.8M | $689.6M | ||
| Q3 25 | $166.1M | $717.2M | ||
| Q2 25 | $176.6M | $732.2M | ||
| Q1 25 | $102.0M | $757.3M | ||
| Q4 24 | $114.8M | $779.7M | ||
| Q3 24 | $121.9M | $616.1M | ||
| Q2 24 | $124.6M | $630.0M |
总债务MSBIZLAB
| Q1 26 | $33.2M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益MSBIZLAB
| Q1 26 | $569.5M | — | ||
| Q4 25 | $565.5M | $715.5M | ||
| Q3 25 | $584.0M | $759.9M | ||
| Q2 25 | $573.7M | $791.7M | ||
| Q1 25 | $571.4M | $810.8M | ||
| Q4 24 | $710.8M | $840.9M | ||
| Q3 24 | $771.2M | $667.7M | ||
| Q2 24 | $736.8M | $704.2M |
总资产MSBIZLAB
| Q1 26 | $6.5B | — | ||
| Q4 25 | $6.5B | $1.2B | ||
| Q3 25 | $6.9B | $1.2B | ||
| Q2 25 | $7.1B | $1.2B | ||
| Q1 25 | $7.3B | $1.2B | ||
| Q4 24 | $7.5B | $1.2B | ||
| Q3 24 | $7.7B | $985.3M | ||
| Q2 24 | $7.7B | $987.4M |
负债/权益比MSBIZLAB
| Q1 26 | 0.06× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流MSBIZLAB
| Q1 26 | — | — | ||
| Q4 25 | $125.7M | $-26.0M | ||
| Q3 25 | $80.0M | $-32.0M | ||
| Q2 25 | $28.1M | $-31.0M | ||
| Q1 25 | $24.7M | $-61.7M | ||
| Q4 24 | $176.5M | $-55.8M | ||
| Q3 24 | $46.5M | $-26.8M | ||
| Q2 24 | $31.4M | $-42.2M |
自由现金流MSBIZLAB
| Q1 26 | — | — | ||
| Q4 25 | $120.3M | $-26.7M | ||
| Q3 25 | $78.6M | $-35.0M | ||
| Q2 25 | $26.7M | $-33.9M | ||
| Q1 25 | $22.9M | $-63.2M | ||
| Q4 24 | $169.6M | $-58.4M | ||
| Q3 24 | $44.4M | $-28.2M | ||
| Q2 24 | $29.9M | $-42.9M |
自由现金流率MSBIZLAB
| Q1 26 | — | — | ||
| Q4 25 | 140.6% | -21.0% | ||
| Q3 25 | 96.9% | -30.4% | ||
| Q2 25 | 32.4% | -31.1% | ||
| Q1 25 | 30.1% | -59.9% | ||
| Q4 24 | 180.6% | -53.8% | ||
| Q3 24 | 47.9% | -27.7% | ||
| Q2 24 | 32.9% | -42.9% |
资本支出强度MSBIZLAB
| Q1 26 | — | — | ||
| Q4 25 | 6.2% | 0.5% | ||
| Q3 25 | 1.7% | 2.6% | ||
| Q2 25 | 1.7% | 2.6% | ||
| Q1 25 | 2.4% | 1.5% | ||
| Q4 24 | 7.3% | 2.4% | ||
| Q3 24 | 2.3% | 1.3% | ||
| Q2 24 | 1.7% | 0.7% |
现金转化率MSBIZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 10.58× | — | ||
| Q2 25 | 2.33× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.28× | — | ||
| Q2 24 | 1.22× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MSBI
| Net Interest Income | $57.4M | 72% |
| Noninterest Income | $22.1M | 28% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
